Screener
Halozyme Therapeutics HALO Payments for Repurchase of Common Stock
Payments for Repurchase of Common Stock at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The source filing: Halozyme Therapeutics’s 10-Q, filed November 3, 2025.
- Filed
- Nov 3, 2025
- Fiscal quarter
- Q3 FY2025
- Calendar quarter
- Q3 2025
- Accession
- 0001159036-25-000045
| Line item | Nine Months Ended / September 30, 2025 | Nine Months Ended / September 30, 2024 |
|---|---|---|
| Purchases of property and equipment | (5,543) | (7,644) |
| Net cash provided by (used in) investing activities | 195,975 | (292,203) |
| Financing activities | ||
| Repurchase of common stock | (342,372) | — |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | 17,683 | 27,554 |
| Net cash (used in) provided by financing activities | (324,689) | 27,554 |
| Net increase in cash and cash equivalents | 303,815 | 35,948 |
| Cash and cash equivalents at beginning of period | 115,850 | 118,370 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's payments for repurchase of common stock?
- Halozyme Therapeutics (HALO) reported payments for repurchase of common stock of $38.88M in Q3 2025.
- What is the long-term trend for Halozyme Therapeutics's payments for repurchase of common stock?
- Over 2 years (2021 to 2024), Halozyme Therapeutics's payments for repurchase of common stock has grown at a -14.2% compound annual growth rate (CAGR), from $339.74M to $250M.
- What does payments for repurchase of common stock mean?
- Payments for Repurchase of Common Stock
Ask your AI about Halozyme Therapeutics's payments for repurchase of common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude